BIOS Capital Management, LP
Follow13F filer, CIK 1813845, Fort Worth, TX
BIOS Capital Management, LP reported $94,098,846 across 6 holdings for the quarter ended 2024-12-31, in a 13F-HR/A filed 2025-02-18.
Filed (acceptance time not in the bulk data set), ingested 13F-HR/A 0001104659-25-014450
- Period
- 2024-12-31
- Reported value
- $94.1M
- Holdings
- 6
- Top 10 weight
- 100%
- New
- Sold out
Part of the filer group BIOS Capital Management, LP
How groups are builtHoldings, Q4 2024
Share positions as resolved from 13F-HR/A 0001104659-25-014450, largest first. % of portfolio is the value over $94,098,846, the sum of the share positions whose value is usable for ratios (method).
| Security | History | Shares | Value | % of portfolio | Change | Latest event | Timeline |
|---|---|---|---|---|---|---|---|
| ACTUACTUATE THERAPEUTICS INC | 9,893,651 | $78.8M | 83.69% | Timeline | |||
| CGTXCOGNITION THERAPEUTICS INC | 6,000,000 | $4.21M | 4.47% | Timeline | |||
| RNTXREIN THERAPEUTICS INC | 1,690,751 | $3.89M | 4.13% | Timeline | |||
| LTRNLANTERN PHARMA INC | 1,207,709 | $3.85M | 4.09% | Timeline | |||
| IN8BIO INCIN8BIO INC | 8,600,001 | $2.21M | 2.35% | ||||
| IRDOPUS GENETICS INC | 995,249 | $1.18M | 1.26% | Timeline |
How Q4 2024 was built
Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).
| Filing | Role | Amendment | Filed | Accepted | Ingested |
|---|---|---|---|---|---|
| 13F-HR 0001104659-25-010964 | superseded | 2025-02-10 | acceptance time not in the bulk data set | ||
| 13F-HR/A 0001104659-25-014450 | base | restatement | 2025-02-18 | acceptance time not in the bulk data set |